A systematic review of transfusion-associated graft-versus-host disease

Blood

Volumn 126, Issue 3, 2015, Pages 406-414

  Kopolovic, Ilana ^a   Ostro, Jackie ^a   Tsubota, Hideki ^b,h   Lin, Yulia ^a,c   Cserti Gazdewich, Christine M ^d   Messner, Hans A ^e   Keir, Amy K ^f   DenHollander, Neal ^d   Dzik, Walter S ^g   Callum, Jeannie ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HLA ANTIGEN; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; STEROID; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BLOOD; BLOOD TRANSFUSION; BONE MARROW APLASIA; BONE MARROW TRANSPLANTATION; DIARRHEA; ERYTHROCYTE; FEVER; HLA TYPING; HUMAN; IMMUNE DEFICIENCY; INTRAUTERINE BLOOD TRANSFUSION; PANCYTOPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; ADVERSE EFFECTS; GRAFT VS HOST DISEASE;

BLOOD TRANSFUSION; GRAFT VS HOST DISEASE; HUMANS;

EID: 84937681869     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-620872     Document Type: Review

References (44)

1. Dwyre DM, Holland PV. Transfusion-associated graft-versus-host disease. Vox Sang. 2008;95(2):85-93.
2. Rühl H, Bein G, Sachs UJ. Transfusion-associated graft-versus-host disease. Transfus Med Rev. 2009;23(1):62-71.
3. Uchida S, Tadokoro K, Takahashi M, Yahagi H, Satake M, Juji T. Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood. Transfus Med. 2013;23(6):416-422.
4. Brubaker DB. Human posttransfusion graft-versus-host disease. Vox Sang. 1983;45(6):401-420.
5. Ohto H, Anderson K. Survey of transfusion associated graft versus host diseas. Transfus Med Rev. 1996;10(1):31-43.
6. Center for Disease Control and Prevention. National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. Atlanta, GA: Center for Disease Control and Prevention; 2014.
7. Terasaki PI. Identification of the type of blood-cell responsible for the graft-versus-host reaction in chicks. J Embryol Exp Morphol. 1959;7:394-408.
8. Simonsen M. The impact on the developing embryo and newborn animal of adult homologous cells. Acta Pathol Microbiol Scand. 1957;40(6):480-500.
9. Hathaway WE, Githens JH, Blackburn WR, Fulginiti V, Kempe CH. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. Probable human runt disease. N Engl J Med. 1965;273(18):953-958.
10. Naiman JL, Punnett HH, Lischner HW, Destiné ML, Arey JB. Possible graft-versus-host reaction after intrauterine transfusion for Rh erythroblastosis fetalis. N Engl J Med. 1969;281(13):697-701.
11. Hong R, Gatti RA, Good RA. Hazards and potential benefits of blood-transfusion in immunological deficiency. Lancet. 1968;2(7564):388-389.
12. Shimoda T. On postoperative erythroderma. Geka. 1955;17:487-492.
13. Weiden P. Graft-v-host disease following blood transfusions. Arch Intern Med. 1984;144(8):1557-1558.
14. Greenbaum BH. Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol. 1991;9(10):1889-1902.
15. King KE, Ness PM. How do we prevent transfusion-associated graft-versus-host disease in children? Transfusion. 2011;51(5):916-920.
16. Shivdasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med. 1993;328(11):766-770.
17. Thaler M, Shamiss A, Orgad S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med. 1989;321(1):25-28.
18. Vogelsang GB. Transfusion-associated graft-versus-host disease in nonimmunocompromised hosts. Transfusion. 1990;30(2):101-103.
19. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323(5):315-321.
20. Perkins HA. Should all blood from related donors be irradiated? Transfusion. 1992;32(4):302-303.
21. U.S. Nuclear Regulatory Commission. Strategy for the security and use of cesium-137 chloride sources. Available at: http://www.nrc.gov/reading-rm/doc-collections/commission/secys/2008/secy2008-0184/2008-0184scy.pdf. Accessed May 7, 2015.
22. Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion. 1999;39(2):128-134.
23. Pinnarò P, Soriani A, D'Alessio D, et al. Implementation of a new cost efficacy method for blood irradiation using a non dedicated device. J Exp Clin Cancer Res. 2011;30:7.
24. Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components. BCSH Blood Transfusion Task Force. Available at: http://www.bcshguidelines.com/documents/irrad-bcsh-072010.pdf. Accessed May 7, 2015.
25. Bolton-Maggs P, Chapman C, Mistry H, Williamson L, Cohen H. Continued absence of transfusion-associated graft versus host disease despite failures to provide irradiated products to patients at risk - more than a decade of data from SHOT. Br J Haematol. 2012;157:3-4.
26. Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion. 2007;47(8):1455-1467.
27. Masse M. Universal leukoreduction of cellular and plasma components: process control and performance of the leukoreduction process. Transfus Clin Biol. 2001;8(3):297-302.
28. Dzik S, Aubuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev. 2000;14(1):34-52.
29. McCarty JR, Raimer SS, Jarratt M. Toxic epidermal necrolysis from graft-vs-host disease. Occurrence in a patient with thymic hypoplasia. Am J Dis Child. 1978;132(3):282-284.
30. Steiner ME, Assmann SF, Levy JH, et al. Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7). Transfus Apheresis Sci. 2010;43(1):107-116.
31. Lacroix J, Hébert P, Fergusson D, et al; ABLE study group. The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. Transfus Med Rev. 2011;25(3):197-205.
32. Aubron C, Nichol A, Cooper DJ, Bellomo R. Age of red blood cells and transfusion in critically ill patients. Ann Intensive Care. 2013;3(2):1-11.
33. Cotton BA, Podbielski J, Camp E, et al; Early Whole Blood Investigators. A randomized controlled pilot trial of modified whole blood versus component therapy in severely injured patients requiring large volume transfusions. Ann Surg. 2013;258(4):527-532, discussion 532-533.
34. Shehata N, Forster A, Lawrence N, et al. Changing trends in blood transfusion: an analysis of 244,013 hospitalizations. Transfusion. 2014;54(10 Pt 2):2631-2639.
35. Wagner FFFW, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion. 1995;35(4):284-291.
36. Charpentier F, Bracq C, Bonin P, Berling P, Duedari N. HLA-matched blood products and posttransfusion graft-versus-host disease. Transfusion. 1990;30(9):850.
37. Ohto H, Yasuda H, Noguchi M, Abe R. Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion. 1992;32(7):691-693.
38. Hutchinson K, Kopko PM, Muto KN, et al. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002;42(12):1567-1572.
39. Hisatomi K, Hirano A, Okuda K, et al. [Post-transfusional syndrome like graft versus host disease]. Nippon Geka Gakkai Zasshi. 1993;94(4):334-340.
40. Hull RJ, Bray RA, Hillyer C, Swerlick RA. Transfusion-associated chronic cutaneous graft-versus-host disease. J Am Acad Dermatol. 1995;33(2 Pt 2):327-332.
41. Murakawa M, Okamura T, Harada M, et al. Disseminated intravascular coagulation in transfusion-associated graft-versus-host disease. Report of two cases. Ann Clin Lab Sci. 1995;25(1):31-38.
42. Prince M, Szer J, van der Weyden MB, Pedersen JS, Holdsworth RF, Whyte G. Transfusion associated graft-versus-host disease after cardiac surgery: response to antithymocyte-globulin and corticosteroid therapy. Aust N Z J Med. 1991;21(1):43-46.
43. Zulian GB, Roux E, Tiercy JM, et al. Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br J Haematol. 1995;89(1):83-89.
44. Siimes MA, Koskimies S. Chronic graft-versus-host disease after blood transfusions confirmed by incompatible HLA antigens in bone marrow. Lancet. 1982;1(8262):42-43.